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Background: Adipose tissue-derived stem cells (ADSCs), a type of mesenchymal stem cells (MSCs), have great
potential as therapeutic agents in regenerative medicine. Numerous animal studies have documented the
multipotency of ADSCs, showing their capabilities to differentiate into tissues such as muscle, bone, cartilage, and
tendon. However, the safety of autologous ADSC injections into human joints is only beginning to be understood
and the data are lacking.
Methods: Between 2009 and 2010, 91 patients were treated with autologous ADSCs with platelet-rich plasma (PRP)
for various orthopedic conditions. Stem cells in the form of stromal vascular fraction (SVF) were injected with PRP
into various joints (n = 100). All patients were followed for symptom improvement with visual analog score (VAS)
at one month and three months. Approximately one third of the patients were followed up with third month
magnetic resonance imaging (MRI) of the injected sites. All patients were followed up by telephone questionnaires
every six months for up to 30 months.
Results: The mean follow-up time for all patients was 26.62 ± 0.32 months. The follow-up time for patients who
were treated in 2009 and early 2010 was close to three years. The relative mean VAS of patients at the end of one
month follow-up was 6.55 ± 0.32, and at the end of three months follow-up was 4.43 ± 0.41. Post-procedure MRIs
performed on one third of the patients at three months failed to demonstrate any tumor formation at the implant
sites. Further, no tumor formation was reported in telephone long-term follow-ups. However, swelling of injected
joints was common and was thought to be associated with death of stem cells. Also, tenosinovitis and tendonitis in
elderly patients, all of which were either self-limited or were remedied with simple therapeutic measures, were
common as well.
Conclusions: Using both MRI tracking and telephone follow ups in 100 joints in 91 patients treated, no neoplastic
complications were detected at any ADSC implantation sites. Based on our longitudinal cohort, the autologous and
uncultured ADSCs/PRP therapy in the form of SVF could be considered to be safe when used as percutaneous local
injections.
Keywords: Mesenchymal stem cell, Adipose tissue-derived stem cells, Platelet-rich plasma, Complications, Safety,
Orthopedics* Correspondence: sangheelee@mju.ac.kr
3National Leading Research Laboratory, Department of Biological Sciences,
Myongji University, 116 Myongjiro, Yongin, Gyeonggido 449-728, Republic of
Korea
Full list of author information is available at the end of the article
© 2013 Pak et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Pak et al. BMC Musculoskeletal Disorders 2013, 14:337 Page 2 of 8
http://www.biomedcentral.com/1471-2474/14/337Background
Mesenchymal stem cells (MSCs), including ADSCs, have
great potentials as a future therapeutic agent in the field
of regenerative medicine. This has created much in vitro
[1-3], in vivo [4-14], and clinical [15-26] experimenta-
tions on MSCs. MSCs can be readily extracted from
bone marrow of hip and spine, and adipose tissue of ab-
domen, thigh and hips [27,28]. These extracted MSCs
have potentials to differentiate into bone, cartilage, ten-
don, muscle, and other tissues [15-17]. Such capabilities
of MSCs to differentiate into bones and cartilage have
been documented by numerous animal studies [9-14].
Also, there have been few reports of successful regener-
ation of bone and cartilage in humans by using various
MSCs [16-26], particularly ADSCs [19-23].
\The platelets contain critical growth factors and media-
tors of tissue repair pathways. Activation of platelets with
calcium chloride has been shown to induce immediate
platelet growth factor release in vitro [29]. The platelet
rich plasma (PRP) obtained from autologous blood con-
tains a high concentration of stored autologous growth
factors. By exposing PRP to calcium chloride, degranula-
tion of platelet is induced. PRP has been successfully used
as a cell culture additive to facilitate growth and differenti-
ation of autologous MSCs [30-33].
However, the safety data for using the autologous
MSC therapy is lacking. Although Centeno et al. has re-
ported safety and complication rate of using autologous
bone marrow derived stem cells in orthopedic applica-
tions [34], there has not been any safety report on using
ADSCs for human orthopedic applications. One of the
safety issues that need to be addressed is the potential of
these stem cells becoming neoplasms. This concern was
brought on by reports of chromosomal abnormalities in
MSCs (not including ADSCs) that have been cultured
in vitro [35-38]. However, when these cells are cultured
less than 60 days in vitro, they pose no detectable risk of
cell mutation or tumor formation, as previously reported
[39]. Further, autologous MSCs that have been used for
cartilage repair in humans also indicate that they form
no tumors during long-term follow-up [26]. The few
early human clinical trials using MSCs completed thus
far support the conclusion that MSCs are safe as thera-
peutic agents [30,34,40]. However, these MSCs were not
including ADSCs.
The purpose of this study was to examine the safety
profile of ADSCs along with PRP for human orthopedic
applications into articular joints.
Methods
In 2009, Korean Food and Drug Administration (KFDA)
has approved medical uses of autologous ADSCs with
minimal manipulation [41]. From November 2009 until
December 2010, 91 patients with 100 articular jointswere treated with autologous ADSCs in the form of stro-
mal vascular fraction (SVF) along with autologous PRP.
The mixture of ADSCs and PRP were percutaneously
injected into knees, hips, low backs, and ankles. After the
completion of the treatment, all patients were followed for
three months. At the third month, some of the patients
were also followed up with high field MRI of the implant
sites. Afterwards, all patients were followed up with tele-
phone questionnaires every six months: at 6, 12, 18, 24,
and 30 months.
This study was in compliance with the Declaration of
Helsinki and regulation guidelines of KFDA. The written
informed consent for participation in the study was ob-
tained from participants. According to Korean law
(Rules and Regulations of the Korean Food and Drug
Administration), questionnaire and register based studies
do not need approval by ethical and scientific commit-
tees, and do not require informed consent [41]. All data
was de-identified and analyzed anonymously.Inclusion and exclusion criteria and outcome endpoints of
patients
For all patients, aspirin, NSAIDS, or any other form of
anticoagulant therapy were stopped at least seven days
prior to liposuction and resumed one week after. Aspirin
were continued to be withheld until the last day of PRP
injection.
The inclusion criteria, exclusion criteria, and outcome
endpoints were listed as follows: Inclusion criteria: (i)
age 18 and older; (ii) chronic or degenerative joint dis-
ease causing significant functional disability and/or pain;
(iii) the failure of conservative treatments; and (iv) an
unwillingness to proceed with surgical intervention.
Exclusion criteria: (i) active inflammatory or connective
tissue disease thought to impact pain condition (i.e., lupus,
rheumatoid arthritis, and fibromyalgia); (ii) active non-
corrected endocrine disorder that might impact pain con-
dition (i.e., hypothyroidism and diabetes); (iii) active
neurologic disorder that might impact pain condition (i.e.,
peripheral neuropathy and multiple sclerosis); (iv) pul-
monary and cardiac disease uncontrolled with medication
usage; (v) history of active neoplasm within the past five
years; (vi) blood disorders documented by abnormal
complete blood count (CBC) within three months includ-
ing severe anemia, thrombocytopenia, leukocytosis and/or
leukopenenia; and (vii) medical conditions precluding the
injection procedures.
Outcome endpoints (pain score, imaging, and tele-
phone questionnaires): (i) pre-treatment visual analog
scale (VAS); (ii) VAS at one month after the procedure;
(iii) VAS at three months after the procedure; (iv) MRI
imaging within three months before the ADSC injection
procedure; and (v) MRI imaging at three months after
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months: at 6, 12, 18, 24, and 30 months.Liposuction procedure
Patients were restricted from taking corticosteroids, as-
pirin, non-steroidal anti-inflammatory drugs (NSAIDs),
and oriental herb medications for minimum one week
prior to the liposuction.
For the liposuction procedure, the patients were se-
dated with propofol 2 mg IV push and 20–30 mg/h rate
of continuous infusion.
Using tumescent solution (40 mL of lidocaine [20 g/L]
with 20 mL of Marcaine [5 g/L], 500 mL normal saline,
and 0.5 mL of epinephrine 1:1000), the lower abdomen
area was anesthetized. Next, lipoaspirates were extracted
and separated by gravity. The resulting 100 mL of adipose
tissue with the tumescent solution were then centrifuged
at 1000 g for 5 minutes. The end result was approximately
40 mL of packed adipose tissue, fibrous tissue, red blood
cells and a small number of nucleated cells. An equal
volume of digestive enzyme (0.07% type 1 collagenase;
Adilase, Worthington, Lakewood, NJ, USA) was then
mixed with the centrifuged lipoaspirates at a ratio of 1:1.
The mixture was then digested for 30 min at 37°C while
rotating. After the digestion, the lipoaspirates were centri-
fuged at 100 g for 3 minutes to separate the lipoaspirate
and the enzyme. The left-over enzyme was then removed.
Using 5% dextrose in lactated Ringer’s solution (D5LR),
the lipoaspirates were washed three times to remove the
collagenase. After each washing, the lipoaspirates were cen-
trifuged at 100 g. After the last centrifuge, approximately
10 mL of ADSCs-containing SVF were obtained [28].
PRP preparation
While preparing the ADSCs, 30 mL of autologous blood
was drawn with 2.5 mL anticoagulant citrate dextrose so-
lution (0.8% citric acid, 0.22% sodium citrate, and 0.223%
dextrose; Baxter Healthcare Corp., Marion, NC, USA).
This was centrifuged at 200 g for 10 minutes. The super-
natant was drawn and spun at 1000 g for 5 minutes. The
supernatant was drawn and discarded. The resulting 2 mL
buffy coat (PRP) was mixed with 10 mL of ADSCs-
containing SVF. To this mixture, 0.5% (w/v) hyaluronic
acid (1 mL; Huons, Chungbuk, Korea) was added as a scaf-
fold. This mixture was again mixed with CaCl2 at a ratio of
10:2 (PRP to CaCl2) for activation of the platelets. This au-
tologous PRP mixture was freshly prepared on the same
day of liposuction. Afterwards, when patient visited for
weekly PRP injection, it was freshly prepared each time.
ADSCs injection with PRP
On the day of liposuction, ADSCs and PRP were pre-
pared within the same surgical procedure. In order toinject ADSCs with PRP, the patients’ joints were pre-
pared by sterile technique and were anesthetized with
2% lidocaine. Then, the mixture of ADSCs, PRP, hyalur-
onic acid, and CaCl2 was injected into the joint under
the ultrasound guidance at an aseptic room.
The patients were then instructed to remain still for
30 minutes to allow for cell attachment. As they were
discharged to home, the patients were instructed to
maintain activity as tolerated.
The patients returned for four additional autologous
PRP injections that were freshly prepared with CaCl2
each week over one month period.
The follow-up disease surveillance questionnaires
All patients were followed up with telephone question-
naires every six months: at 6, 12, 18, 24, and 30 months.
Each time, patients were asked the following questions:
(i) did you experience any complications (i.e., infection,
illness, etc.) you believe may be due to the procedure? If
yes or maybe, please explain; and (ii) have you been di-
agnosed with any form of cancer since the procedure? If
yes, please explain.
Statistics
Statistical analysis was performed using SPSS software ver-
sion 20.0 (SPSS Inc., New York, USA). There were three
groups (pre-treatment, one month after treatment, and
three months after treatment) and Levene’s test results re-
vealed that the variance of the dependent variable (relative
VAS) was not equal across groups. Therefore, Kruskall-
Wallis test was conducted to compare the means of three
groups. To detect significant differences among groups,
post hoc testing was performed by Mann–Whitney U
tests. A p-value below 0.05 was considered statistically
significant.
Results
Patient demographics and areas treated
From November 18, 2009 until December 17, 2010, a total
of 100 joints were treated in 91 patients. As of October
2012, the mean follow-up time for all patients was 26.62 ±
0.32 months. 100 procedure follow-up contacts occurred
at 12 months or more, 78 contacts at 24 months or more,
and 17 contacts at 30 months (Table 1). The first patient
was treated on November 18, 2009. Thus, the follow-up
time for patients who were treated in 2009 and early 2010
was close to three years.
There were a total of four patients in 2009. They were
all female and their age was 61, 57, 71, and 77, respect-
ively. Of these four, the first patient received two injec-
tions of ADSCs into the knee: the first dose was injected
on November 18, 2009, and the second dose was
injected on April 28, 2010. The first dose of the first pa-
tient did not include PRP. Thus, the procedure was
Table 1 Number of follow-up contacts at each end-point
in the six age ranges
Age range
(years)
Number of follow-up contacts
1 mo. 3 mo. 12 mo. 24 mo. 30 mo.
18 ~ 29 9 9 9 7 2
30 ~ 39 15 15 15 12 -
40 ~ 49 23 23 23 15 3
50 ~ 59 19 19 19 15 4
60 ~ 69 21 21 21 18 4
70 ~ 80 13 13 13 11 4
-: no contact.
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total of 91 patients, three patients received two treat-
ments of identical joints and six patients received two
treatments at different joints. Nine patients underwent
two procedures. Of the nine, three patients received
ADSCs on the same knee joints and the other six pa-
tients received ADSCs on the other knees. The second
procedure of all nine patients occurred with 3 ~ 4 months
after the first. Of these nine patients, only one patient
did not obtain MRI after the first and second doses of
ADSCs. All other eight patients obtained MRI after three
months from each first and second ADSCs/ PRP treat-
ment. Thus, the total number of joints treated (n = 100)
is higher than the number of patients (n = 91) treated.
The mean age was 51.23 ± 1.50, with the range being
18–78 years; 45 patients were male and 46 female. The
age of patients was relatively evenly distributed (Table 1).
Nine patients underwent more than one procedure. In
all, the patients underwent 74 knee procedures (distrib-
uted with 67.6% in the age range of 40 ~ 69), 22 hip pro-
cedures (distributed with 81.8% in the age range of 18 ~
49), two low back procedures, and two ankle procedures
(Table 2). Of the 22 hip procedures, 15 were avascular
necrosis and seven were hip osteoarthritis. All 74 knees
and two ankles had diagnosis of osteoarthritis while the
two low back procedures had spinal disc herniation.Table 2 Frequency of sites treated in all patients
separated into the six age ranges
Age range
(years)
Number of sites treated
Knee Hip Low back Ankle
18 ~ 29 4 5 - -
30 ~ 39 8 6 - 1
40 ~ 49 14 7 1 1
50 ~ 59 17 2* - -
60 ~ 69 19 2* - -
70 ~ 80 12 - 1 -
-: no site treated; *: two sites including hip bone and hip cartilage.Pre-procedure MRIs were carried out on 86 patients.
Among these, 27 patients also underwent post-procedure
MRIs. Due to financial reasons, 59 patients refused to
undergo post-procedure MRIs. Mean time for last MRI
follow-up since the procedure was 3.11 ± 0.12 months.
MRIs (as read by both examiners and physicians) were
negative for any evidence of tumor formation at the im-
plantation site.Pain measurements
To assess the symptom improvement of the treatment,
VAS was analyzed. For all patients, VAS was marked at
10 before treatments. The patients were followed up
consequently with VAS at one month and at three
months after the initial injection. Thus, the VAS results
are relative to the VAS marked before the initial ADSCs-
containing SVF injections.
The relative mean VAS of 96 joints at the end of one
month follow-up was 6.55 ± 0.32, and at the end of three
months follow-up was 4.43 ± 0.41 (Figure 1). The relative
mean VAS of cartilage repair of 81 joints (74 knees and
seven hips; excluding two ankles and two low backs) at
the end of one month follow-up was 6.53 ± 0.63 and at
the end of three months follow-up was 4.30 ± 0.74
(Figure 1). The lowest values of the relative mean VAS
were in the age range group of 70 ~ 80 (Table 3). The
relative mean VAS of bone regeneration (n = 15) in hips
of AVN patients at end of one month follow-up was
6.64 ± 0.32 and at end of three months follow-up was
5.17 ± 0.32 (Figure 1). Two low back and ankle patients
reported minimal clinical improvement and did not ob-
tain post procedure MRIs.Figure 1 Pain measurements of patients. VAS and AVN are visual
analog scale and avascular necrosis, respectively. Combined relative
mean VAS scores (right three bars) are those of 96 joints (hip bone
[left bars]: 15 joints; knee and hip cartilage [middle bars]: 81 joints).
Error bars indicate standard errors. * = p < 0.05.
Table 3 Pain measurements of patients separated into the six age ranges
Age range
(years)
Relative mean VAS score
Hip bone (AVN) Knee and Hip cartilage Combined
Pre 1 mo. 3 mo. Pre 1 mo. 3 mo. Pre 1 mo. 3 mo.
18 ~ 29 10 8.50 ± 0.33 - 10 5.80 ± 1.40 3.00 ± 0.62 10 6.57 ± 1.53 3.00 ± 1.38
30 ~ 39 10 5.20 ± 0.83 3.40 ± 0.54 10 7.71 ± 0.75 5.86 ± 0.89 10 6.67 ± 1.30 4.83 ± 1.64
40 ~ 49 10 6.33 ± 0.25 6.33 ± 0.23 10 6.38 ± 1.67 4.45 ± 1.59 10 6.28 ± 1.71 4.89 ± 1.97
50 ~ 59 10 10* 6* 10 6.81 ± 1.10 4.21 ± 1.27 10 7.20 ± 1.16 4.31 ± 1.99
60 ~ 69 10 9* 9* 10 6.75 ± 1.85 4.97 ± 1.60 10 6.75 ± 1.83 5.21 ± 1.92
70 ~ 80 - - - 10 5.00 ± 0.69 2.44 ± 0.62 10 5.00 ± 0.97 2.44 ± 1.93
Pre: pre-treatment; 1 mo.: one month after treatment; 3 mo.: three months after treatment; -: not determined; *: VAS score of one patient.
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The complications of the concern can be summarized as
follows: (i) pain and swelling: 37% of 100 joints treated
joints reported development of pain and swelling after one
day after the ADSCs/PRP injection. Pain swelling im-
proved with cold compressions and routine oral NSAIDs
prescriptions given on the first day of discharge. These
complications were detected only in the knee joints
treated. Among these patients, 51% were older than 50;
(ii) infection: 0%; (iii) neurologic: 1% (a hemorrhagic stroke
approximately two weeks after the procedure); (iv) tumor:
0%: (v) tendonitis/tenosynovitis: 22%. Among these pa-
tients, 68% were older than 60 and started to occur after
6 ~ 8 weeks of the procedure; and (vi) skin: 1% (a localized
rash around the injection site after 1 ~ 2 days of the pro-
cedure) (Table 4).
Discussion
Our results show that autologous and uncultured
ADSCs/PRP therapy in the form of SVF could be con-
sidered to be safe when used as percutaneous local
injections.
ADSCs were extracted using collagenases, which were
later removed by washing the ADSCs with D5LR solu-
tion three times. After all three washings, the total
amount of collagenase contained in the ADSCs was un-
detectable (data not shown). Therefore, it would be very
doubtful if such undetectable amount of collagenase




Pain and swelling with improvement Infection
18 ~ 29 3 -
30 ~ 39 5 -
40 ~ 49 10 -
50 ~ 59 10 -
60 ~ 69 4 -
70 ~ 80 5 -
-: no complication.However, it can be assumed that some of the cells
injected into the joints, including red blood cells and
ADSCs, would not have survived, as previously reported
[42]. Probably such non-viable cells surmount an inflam-
matory reaction, causing pain and swelling. A recent re-
port supports this notion [43]. Such pain and swelling
subside gradually with oral intakes of NSAIDs and cold
compression. The frequency of these complications was
more than that of other report using culture-expanded
bone marrow-derived MSCs [34].
After 6–8 weeks of ADSCs and PRP injection of knee
joints, some elderly patients complained of knee pain
secondary to tenosinovitis and tendonitis. These symp-
toms usually occurred in elderly patients over the age of
60 (15 of 22 patients), as previously described [44].
These symptoms improved with NSAIDs and resolved
with trigger point injections with triamcinolone at third
or fourth months. The exact cause of these symptoms is
not clear. It can be postulated that knee posture may be
the cause. Cartilage regeneration, decreased mobility
during the procedure, or increased mobility after the
procedure may cause the positioning of the knee joint to
be changed, resulting the tendons and ligament to strain,
as previously reported [45].
One patient experienced a localized rash around the
injected site of the knee. Another patient experienced a
hemorrhagic stroke. Although the percentage of these
complications is greater than 1% of the total patient popu-
lation of this group, these two are more of co-incidences.nges
age of treated joints
Neurologic Tumor Tendonitis/ Tenosinovitis Skin
- - - -
- - - -
- - 2 -
- - 5 -
1 - 10 1
- - 5 -
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would be the synthetic hyaluronic acid that was injected
as a scaffold material. As for the hemorrhagic stroke, no
other patient experienced such symptoms in the other pa-
tient group treated after the year 2010. Further, in the case
of hemorrhagic stroke, it is difficult to assume that any
form of cells injected locally with PRP were re-absorbed
or transferred to blood stream, causing hemorrhagic
stroke. In addition, recent research by Horie et al. demon-
strated that MSCs implanted in a joint remain localized to
the transplant site [46].
According to the results of the analysis of pain scores
and telephone questionnaires from 100 joints, there has
been no report of tumor formation at the implant sites.
Further, there was no evidence of tumor formation in 27
joints that were imaged by MRI. This study is the first re-
port on ADSCs safety in clinical applications. While it is
possible that tumors may still form at some time beyond
the average follow-up period presented in our data, this
possibility decreases at an exponential rate. MSCs repli-
cate every 2–4 days in vitro expansion [35-37]. Thus, if a
tumor were to form at the implanted site, it might have
been discernible within few months by a high field MRI.
Patients’ VAS after the ADSCs/PRP treatment improved
50-60%, and this was statistically significant (Figure 1). The
pain improvement can be attributed to the probable regen-
eration of the damaged tissues that have been documented
by MRI in some of the patients. However, no patient re-
ported 100% resolution of the pain. Many possibilities exist
for the explanation of incomplete resolution of the pain.
One of the reasons would be the fact that the extent of the
regeneration was achieved only partially. Another possible
rationale for the incomplete resolution of the pain is prob-
ably the fact that the osteoarthritis and AVN are joint dis-
orders as a whole, not just degeneration of only cartilage
and bone, respectively.
The two low back and the two ankle patients reported
minimal clinical improvement. Many reasons exist for
possible rationale of the minimal pain improvement.
Also, quantity and quality of MSCs are important. An-
other important factor is properly targeting the site for
injection [46], especially if the target site has limited
space. With regards to low backs, uncertainty exists if
ADSCs were correctly and properly placed in the disc.
As for the ankle, the quantity and quality of ADSCs
injected in the limited joint space could be questioned.
Overall, this study with 100 joint injections of ADSCs,
in the form of SVF, with PRP shows that ADSCs/PRP
treatment is safe and provides long-term pain improve-
ment. However, this study only shows a glimpse of the
possibility of using ADSCs in the field of regenerative
medicine. All patients were offered the third month post-
procedure MRIs, but some patients refused to undergo
post-procedure MRIs due to symptom improvement and/or financial reasons. Therefore, the longer-term (more
than 3 months) follow-ups were conducted based on tele-
phone questionnaires. The measurement of PRP concen-
tration and the assessment of viable ADSCs’ quantity and
quality are necessary. Also, randomized, double blind, and
placebo-controlled studies are needed to confirm the effi-
cacy of ADSCs in various joint diseases.
Conclusions
This retrospective cohort study demonstrated no evi-
dence of neoplastic complications in any implant sites in
91 patients with 100 joints, some of whom were moni-
tored with high field MRI tracking and via general sur-
veillance. In summary, based on this longitudinal cohort,
autologous and uncultured ADSCs/PRP therapy in the
form of SVF can be considered to be safe when used as
percutaneous local injections.
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